RSB expands US market for VBR (vertebral body replacement) tech:
This article was originally published in Clinica
Executive Summary
The US FDA has given RSB Spine the market go-ahead to expand the indication of its InterPlate vertebral body replacement (VBR) system by allowing the product to be used without supplemental fixation. Under the new indication, the device can be used in patients where a less invasive, anterior approach is selected, in conjunction with a standalone implant. The Cleveland, Ohio firm said that compared to use with posterior supplemental fixation, the patient will recover more rapidly, and hospitals will realise "significant" cost savings. It added that marketing submissions for cervical and lumbar interbody indications are expected to follow, as well as new product designs based on the InterPlate platform.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.